The expression of estrogen receptors by breast cancer cells has provided a therapeutic target by using estrogen receptor antagonists, but their use contributes to an unfortunate stimulation of breast cancer development through the pharmacological use of estrogen, the ligand for the estrogen receptor. Here, ESR1 is linked to breast carcinoma.